Third Wave nevertheless got a permanent injunction, but now is getting flak from another flank:
>>MADISON, Wis., Sept. 30 /PRNewswire-FirstCall/ -- Third Wave Technologies Inc. (Nasdaq: TWTI - News) today responded to a lawsuit filed against it by Innogenetics N.V., Gent, Belgium, that alleges Third Wave is infringing one of Innogenetics' hepatitis C virus (HCV) patents. Innogenetics also filed a similar suit against Abbott Laboratories. Both suits were filed in U.S. District Court for the Western District of Wisconsin in Madison, Wis.
"Third Wave is well versed in the HCV patent landscape and has taken great care to understand and respect all the major patents in the field, including those held by Innogenetics," said Kevin Conroy, vice president and general counsel of Third Wave. "Innogenetics' suit lacks a basic understanding of the uniqueness of Third Wave's Invader® chemistry and how it is configured in our HCV analyte-specific reagents. It appears that Innogenetics filed suit against Third Wave without first understanding how our product is designed. In addition to our belief that Third Wave is not infringing Innogenetics' patent, we believe the Innogenetics' patent is invalid."
Third Wave and Innogenetics are marketing partners in Europe and have been in discussions about the possible expansion of their distribution partnership.<<
snip
Cheers, Tuck (who is STILL on jury duty) |
